(Total Views: 854)
Posted On: 08/02/2020 5:10:36 PM
Post# of 153988
Vicr,
Same here. Have watched the interview several times. Dr. Patterson is a great source of knowledge due to his vast experience with CCR5/RANTES coming from HIV and the fact that he has the measurements (coming form his very sophisticated lab, I must add).
So he knows the theory and can measure the "reality" of Lero working in the body as time progresses (cytokines, chemokines, T-cells, ratios, IL-6, PVL and so on)
Those two produce a VERY powerful understanding of the "beautiful story" as he often refers to the condition timeline.
The publication of his paper would give "cover" as far as the moa goes to CYDY when presenting the results to FDA.
I think the results will speak by themselves, but, once they do, a peer-reviewed paper published concurrently explaining the science behind the observed benefits will "grease" the wheels of a potential M-M approval (we need to remember that we are in P2 for this condition.
I am looking forward to the publication, the added value will be the "control" data and, the PVL at day 14 and beyond if this is available.
Same here. Have watched the interview several times. Dr. Patterson is a great source of knowledge due to his vast experience with CCR5/RANTES coming from HIV and the fact that he has the measurements (coming form his very sophisticated lab, I must add).
So he knows the theory and can measure the "reality" of Lero working in the body as time progresses (cytokines, chemokines, T-cells, ratios, IL-6, PVL and so on)
Those two produce a VERY powerful understanding of the "beautiful story" as he often refers to the condition timeline.
The publication of his paper would give "cover" as far as the moa goes to CYDY when presenting the results to FDA.
I think the results will speak by themselves, but, once they do, a peer-reviewed paper published concurrently explaining the science behind the observed benefits will "grease" the wheels of a potential M-M approval (we need to remember that we are in P2 for this condition.
I am looking forward to the publication, the added value will be the "control" data and, the PVL at day 14 and beyond if this is available.
(4)
(0)
